BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Britain Courts Anthropic Amid US Defense Department Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 06, 2016 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, CEO, will provide a corporate overview and business update at the Rodman & Renshaw 18th Annual Global Investment Conference, taking place in New York City, New York, September 11-13, 2016.
Presentation Details:
Title: Rodman & Renshaw 18th Annual Global Investment Conference
Date: Monday, September 12
Time: 2:35 p.m. Eastern Time
Location: The Lotte New York Palace Hotel, New York City
About Foamix
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Mylan.
For more information, please visit www.foamixpharma.com.
Contact: Dorit Hayon, BD Foamix Pharmaceuticals Ltd. +972-8-9316233 [email protected] US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 [email protected]
